Publications by authors named "Gina Reynolds"
Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients.
Mayo Clin Proc Innov Qual Outcomes
April 2022
Objective: To evaluate the magnitude of humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with cancer receiving active therapies.
Patients And Methods: Patients 18 years or older in whom SARS-CoV-2 spike antibody (anti-S Ab) levels were measured after 2 doses of SARS-CoV-2 mRNA vaccines were included. Patients with prior coronavirus disease 2019 (COVID-19) infection or receiving other immunosuppressive therapy were excluded.
Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and systemic symptoms (DRESS) upon initial exposure to alpelisib. Here we describe the clinical-pathological findings and management of our patient with alpelisib-induced life-threatening DRESS syndrome.
View Article and Find Full Text PDFArticle Synopsis
- Increasing data indicate that preexisting immune responses and neoantigen levels are crucial for how well patients respond to immune checkpoint inhibitors (ICIs), with tumor mutational burden (TMB) being a notable biomarker in lung cancer and melanoma.
- In a case study, a patient with HER2-negative breast cancer and high TMB achieved a lasting complete response to ICIs, even with low levels of tumor-infiltrating lymphocytes and PD-L1 negativity, suggesting a unique treatment outcome despite typically unfavorable indicators.
- Analysis of a large cohort revealed that many TMB-high tumors were PD-L1-negative, showing that TMB can still play a valuable role in predicting ICI responses in breast cancer, challenging the notion of relying
Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy.
View Article and Find Full Text PDF